Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784666 · ClinicalTrials.gov registry record · Phase 2
Adjunctive Isradipine for the Treatment of Bipolar Depression
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01784666: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01784666 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01784666, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study investigates the medication isradipine, which is currently approved by the FDA to treat high blood pressure, in the treatment of depression in bipolar disorder. Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsychotics for individuals currently experiencing a major depressive episode. Our hypothesis is that isradipine will be superior to placebo in improving depressive symptoms.
Interventions
- DRUG Placebo
- DRUG Isradipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01784666
The ClinicalTrials.gov registry entry for NCT01784666 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01784666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01784666 about?
NCT01784666 is a clinical study titled "Adjunctive Isradipine for the Treatment of Bipolar Depression". This study investigates the medication isradipine, which is currently approved by the FDA to treat high blood pressure, in the treatment of depression in bipolar disorder. Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsy...
What is the current status of trial NCT01784666?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01784666?
The interventions under investigation include: Placebo (DRUG), Isradipine (DRUG).
Who is sponsoring clinical trial NCT01784666?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.